Categories Earnings, LATEST, Other Industries

Bio-Path’s loss expands in Q2

Biotech company Bio-Path Holdings (NASDAQ: BPTH) reported a loss of $2.5 million or $0.87 per share for the second quarter ended June 30, 2019, compared to a loss of $1.7 million or $2.96 per share for the second quarter ended June 30, 2018. Bio-Path has not generated significant revenues to date. The company’s revenue generation in the future depends on the successful development and eventual commercialization of its drug candidates.

Research and development expenses increased to $1.5 million from $0.8 million in the prior-year quarter, primarily due to the commencement of activities related to Stage 2 of Phase 2 clinical trial in AML.

Read: Arcadia Biosciences (RKDA) swings to profit in Q2

As of June 30, 2019, the company had cash of $17.1 million, compared to $1.0 million at December 31, 2018. Net cash used in operating activities for the six months ended June 30, 2019 was $4.2 million compared to $3.4 million for the comparable period in 2018.

“Throughout the second quarter we continued to execute on our clinical development plans for our innovative RNAi nanoparticle therapeutics,” said CEO Peter Nielsen.

He added, “We are also looking forward to completing Investigational New Drug (IND) enabling studies of BP1003, a novel liposome-incorporated STAT3 oligodeoxynucleotide inhibitor for the treatment of pancreatic cancer, and to file an IND application for a Phase 1 study of BP1003 for the treatment of pancreatic cancer in 2020.”

Bio-Path stock closed down 0.91% at $11.96 yesterday and has dipped 33% in the past three months.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Also Read:  Wayfair posts narrower-than-expected Q4 loss

Most Popular

Cloudera (CLDR) posts narrower loss in Q1, beats estimates

Cloudera Inc. (NYSE: CLDR) reported a narrower loss in the first quarter of 2021 driven by lower costs and expenses as well as higher revenue. The results exceeded analysts' expectations.

CrowdStrike (CRWD): Shift to digital transformation presents huge expansion opportunity

CrowdStrike Holdings Inc. (NASDAQ: CRWD) has witnessed strong momentum with the stock gaining over 96% since the beginning of the year. The company delivered strong results for the first quarter

Why Zscaler (ZS) stock reached all-time high on Monday?

Internet security has been evolving over time, aided by the rapid adoption of cloud computing, the ubiquity of mobile phones, and the growing threats that cause serious problems to enterprises

Tags

Top